Anzeige
Mehr »
Samstag, 09.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JJ99 | ISIN: US04962H5063 | Ticker-Symbol: YAG2
Tradegate
07.08.25 | 19:12
0,680 Euro
+0,44 % +0,003
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ATOSSA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ATOSSA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,6600,70011:39
0,6640,69008.08.

Aktuelle News zur ATOSSA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
01.08.RedChip Companies, Inc.: Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV374ORLANDO, FL / ACCESS Newswire / August 1, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Atossa Therapeutics, Inc. (Nasdaq:ATOS) on the RedChip...
► Artikel lesen
29.07.Atossa Therapeutics stock jumps after FDA provides positive feedback26
29.07.Atossa receives FDA feedback for breast cancer drug development17
29.07.Atossa Therapeutics Inc: Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer103SEATTLE, July 29, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, today announced...
► Artikel lesen
27.06.Atossa Genetics Year-end 2024 slides: (Z)-endoxifen shows promise, expenses decline23
06.06.Ascendiant Capital raises Atossa Genetics stock price target to $7.5026
05.06.Atossa Therapeutics bei Jefferies-Konferenz: Strategische Schritte gegen Brustkrebs32
20.05.Atossa Therapeutics, Inc.: Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22467SEATTLE, WASHINGTON / ACCESS Newswire / May 20, 2025 / Atossa Therapeutics, Inc. (Nasdaq:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines...
► Artikel lesen
ATOSSA THERAPEUTICS Aktie jetzt für 0€ handeln
14.05.Atossa Therapeutics Inc: Atossa Therapeutics Announces Full Results from I-SPY 2 Endocrine-Optimization Sub-Study Evaluating Low-Dose (Z)-Endoxifen294Feasibility endpoint achieved; rapid Ki-67 suppression and substantial MRI-confirmed tumor shrinkage observed with favorable safety profile SEATTLE, May 14, 2025 /PRNewswire/ -- Atossa Therapeutics...
► Artikel lesen
13.05.Atossa Therapeutics GAAP EPS of -$0.05 beats by $0.016
13.05.ATOSSA THERAPEUTICS, INC. - 10-Q, Quarterly Report3
13.05.ATOSSA THERAPEUTICS, INC. - 8-K, Current Report1
13.05.Atossa Therapeutics Inc: Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update257Announced strategic plan to advance (Z)-endoxifen for metastatic breast cancer indication Enhanced (Z)-endoxifen intellectual property portfolio with three new...
► Artikel lesen
05.05.RedChip Companies, Inc.: Atossa Therapeutics and Ainos Interviews Aired on the RedChip Small Stocks, Big Money Show on Bloomberg TV351ORLANDO, FL / ACCESS Newswire / May 5, 2025 / RedChip Companies aired interviews with Atossa Therapeutics, Inc. (Nasdaq:ATOS) and Ainos, Inc. (Nasdaq:AIMD) on the RedChip Small Stocks, Big Money show...
► Artikel lesen
30.04.Atossa wins U.S. patent related to multiple formulation of lead asset7
30.04.Atossa Therapeutics secures new patent for breast cancer drug7
30.04.Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio187SEATTLE, April 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast...
► Artikel lesen
29.04.Atossa stellt Phase-3-Studie zur Brustkrebsprävention vor12
29.04.Atossa outlines phase 3 trial for breast cancer prevention2
29.04.Atossa Therapeutics, Inc.: Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025222SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast...
► Artikel lesen
Weiter >>
48 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,7